Durata Therapeutics, Inc. Presents New Pivotal Phase 3 Clinical Results and New In Vitro Data on Dalbavancin at ICAAC

Published: Sep 11, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

DENVER, Sept. 10, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) today presented clinical trial results from its two Phase 3 DISCOVER ("Dalbavancin for Infections of the Skin COmpared to Vancomycin at an Early Response") 1 and 2 studies and new in vitro data of dalbavancin, further characterizing the effect of the investigational treatment against Gram-positive bacteria. In the two randomized, double-blind clinical studies, dalbavancin was shown to be non-inferior to the comparator regimen, vancomycin with an option to switch to oral linezolid, in treating acute bacterial skin and skin structure infections (ABSSSI).i, ii In both studies, dalbavancin met its primary and secondary endpoints.

Help employers find you! Check out all the jobs and post your resume.

Back to news